Tirzepatide/GLP/GLP-1/Mounjaro/Zepbound

Superiority:

Tirzepatide             NO1 Supplier in China

Tirzepatide is a novel, once weekly, dual GIP/GLP-1 receptor agonist and is under development for the treatment of type 2 diabetes (T2D) and obesity.

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide-GLP-1 receptor agonist.

Product attributes

Brand: Huarong
Model: 2023788-19-2
Place of origin: Shanghai

Custom properties

Tirzepatide is a novel, once weekly, dual GIP/GLP-1 receptor agonist and is under development for the treatment of type 2 diabetes (T2D) and obesity.

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide-GLP-1 receptor agonist.

Trading information

Minimum Order: 10mg/vial, 10 vials/box, MOQ 1 box
Price: 300usd/box，including shipping
Payment: , Credit Card, Bank Transfer
Delivery: 1000000 boxes/week
Delivery: Ships immediately after payment received
Regular packing: 10mg/vial, 15mg/vial，20mg/vial，30mg/vial，10 vials/box.

Tirzepatide is a weekly GIP (glucose dependent Insuli promoting peptide) receptor and GLP-1 (glucagon like peptide-1) receptor agonist. Tirzepatide is a single molecule that can activate GIP and GLP-1 receptors in the human body, which are natural pancreatic hormones. GIP and GLP-1 receptors are present in important appetite regulating regions of the human brain. Tirzepatide has been proven to reduce food intake and regulate fat utilization. Tirzepatide is currently in the third stage of development for treating adults who are obese or overweight and have weight related comorbidities. It is also being studied as a potential drug for treating obesity or overweight with preserved ejection fraction (HFpEF), obstructive sleep apnea (OSA), and non-alcoholic fatty liver disease (NASH). Tilpoleptide is also being studied in chronic kidney disease (CKD) and obesity incidence rate/mortality (MMO).

Tirzepatide was approved by the FDA as Mounjar on May 13, 2022. Tilporide Mounjar is a glucose dependent Insuli promoting polypeptide (GIP) receptor and glucagon like peptide-1 (GLP-1) receptor agonist, which is suitable for auxiliary treatment of diet and exercise, and is used to improve blood glucose control in type 2 diabetes adults.

The pharmacological characteristics of Tirzepatide are mainly manifested in the following aspects. Firstly, telposide can simultaneously activate both GIP and GLP-1 receptors, producing stronger Insuli promoting effects. Secondly, Tirzepatide has long-term efficacy and can continue to exert its effects at a single dose without the need for frequent injections. In addition, telposide also has good tissue distribution and metabolic characteristics, which can effectively reduce blood sugar levels and body weight, and reduce Insuli resistance.


The clinical trials of Tirzepatide have shown its excellent weight loss and hypoglycemic effects. In the SUROUNT-2 trial, participants received treatment with 30, 15, or 5 milligrams of telposide or placebo for a 72 week period. Among them, patients in the 30mg and 15mg groups lost 15.7% and 13.5% of their weight, while those in the placebo group lost 2.3% of their weight. In addition, patients in the 30mg and 15mg groups also showed better results in HbA1c and fasting blood glucose control. These results indicate that tilporide is a potential drug for the treatment of diabetes and obesity.

In addition, telposide is also considered to have a wider range of potential applications. Its application in diseases such as heart failure, obstructive sleep apnea, and non-alcoholic fatty liver disease is also undergoing clinical trials. In HFpEF and OSA patients, telposide is believed to improve symptoms and quality of life, reduce weight, and improve metabolic indicators. In NASH patients, the use of telposide can also reduce liver fat content and improve metabolic indicators. These potential uses provide more opportunities for the future development of telposide